Y. Barrett

发表

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

C. Frost, Jessie Wang, S. Nepal, 2012, British journal of clinical pharmacology.

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor

F. Lee, S. Galbraith, Y. Barrett, 2008, Cancer Chemotherapy and Pharmacology.

Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.

K. Behnia, Rongan Zhang, P. Sleph, 2016, Cell Metabolism.

Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.

A. Shenker, C. Frost, Jessie Wang, 2014, British journal of clinical pharmacology.

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

C. Frost, Jessie Wang, Y. Barrett, 2012, Thrombosis and Haemostasis.

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.

C. Frost, Jessie Wang, Y. Barrett, 2013, British journal of clinical pharmacology.

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

A. Shenker, C. Frost, Jessie Wang, 2013, British journal of clinical pharmacology.

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.

George Scott, Viswanath Devanarayan, Gopi Shankar, 2004, Journal of immunological methods.

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban

A. Shenker, C. Frost, Jessie Wang, 2015, Clinical Pharmacokinetics.

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

A. Shenker, C. Frost, Y. Barrett, 2010, Thrombosis and Haemostasis.

Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor

L. Wallentin, R. Becker, J. Alexander, 2011, Journal of Thrombosis and Thrombolysis.

A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors

R. Knabb, Y. Barrett, Zhaoqing Wang, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants

Y. Barrett, E. Ramacciotti, J. Weitz, 2013, Journal of thrombosis and haemostasis : JTH.

A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma.

H. Pieniaszek, R. Olson, Y. Barrett, 2003, Journal of pharmaceutical and biomedical analysis.

Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia.

R. Wynn, T. Hua, W. Ebling, 2003, Blood.

Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome

L. Wallentin, R. Becker, J. Alexander, 2010, Thrombosis and Haemostasis.

antagonist Roxifiban: implications for the etiology of thrombocytopenia of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa Prospective testing for drug-dependent antibodies reduces the incidence

R. Wynn, W. Ebling, H. Pieniaszek, 2013 .

Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

Viswanath Devanarayan, Russell Weiner, Chad Ray, 2006, Pharmaceutical Research.

Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003).

P. Ji, K. He, Y. Barrett, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Apixaban Single‐Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration

A. Shenker, C. Frost, Y. Barrett, 2021, Clinical pharmacology in drug development.

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects

C. Frost, Jessie Wang, A. Schuster, 2013, Clinical pharmacology : advances and applications.

Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma

C. Frost, Jessie Wang, Y. Barrett, 2017, Thrombosis and Haemostasis.

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

C. Frost, Jessie Wang, Y. Barrett, 2014, Clinical pharmacology : advances and applications.

Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis

R. Knabb, Jessie Wang, Y. Barrett, 2010, Thrombosis and Haemostasis.

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

Viswanath Devanarayan, Michele Fiscella, Lakshmi Amaravadi, 2008, Journal of pharmaceutical and biomedical analysis.

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.

Viswanath Devanarayan, Boris Gorovits, Michael Moxness, 2008, Journal of immunological methods.

Apixaban Treatment Decreases Coagulation Activity in Patients with Acute Deep-Vein Thrombosis.

A. Shenker, R. Knabb, Jessie Wang, 2008 .

Association Between Pulmonary Function and Asthma Symptoms.

A. Fuhlbrigge, Y. Barrett, P. Sullivan, 2019, The journal of allergy and clinical immunology. In practice.

Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist.

W. Ebling, H. Pieniaszek, D. Seiffert, 2007, Journal of pharmaceutical and biomedical analysis.

Automated on-line SPE LC-MS/MS method to quantitate 6beta-hydroxycortisol and cortisol in human urine: use of the 6beta-hydroxycortisol to cortisol ratio as an indicator of CYP3A4 activity.

Shu-Ying Chang, Y. Barrett, Yu Chen Barrett, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.

Rongan Zhang, P. Sleph, T. Kirchgessner, 2016, Cell metabolism.